Acemetacin is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain.
Acemetacin is a non-steroidal anti-inflammatory drug. It is also known as an NSAID. It works by blocking a substance in the body called cyclooxygenase (also known as COX) which is involved in the production of certain irritant chemicals in response to injury or rheumatic disease. By blocking the action of COX, Acemetacin reduces the symptoms of pain and inflammation.
Pain and inflammation in rheumatic disease | Pain and inflammation in other musculoskeletal disorders | Postoperative analgesia BY MOUTH Adult: 120 mg daily in divided doses, then increased if necessary to 180 mg daily in divided doses, dose to be taken with food
Acemetacin reduces the antihypertensive effect of b-blockers. Increase risk of convulsion when used with quinolone. Concurrent use with aspirin, NSAIDs or corticosteroids may increase risk of GI bleeding. Increased risk of methotrexate toxicity when used together.
CONTRA-INDICATIONS Active gastro-intestinal bleeding . active gastro-intestinal ulceration . history of gastrointestinal bleeding related to previous NSAID therapy . history of gastro-intestinal perforation related to previous NSAID therapy . history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) . history of recurrent gastro-intestinal ulceration (two or more distinct episodes) . severe heart failure CAUTIONS Allergic disorders . cardiac impairment (NSAIDs may impair renal function) . cerebrovascular disease . coagulation defects . connective-tissue disorders . Crohn’s disease (may be exacerbated) . elderly (risk of serious sideeffects and fatalities) . epilepsy . heart failure . ischaemic heart disease . parkinsonism . peripheral arterial disease . psychiatric disturbances . risk factors for cardiovascular events . ulcerative colitis (may be exacerbated) . uncontrolled hypertension
Rare Alveolitis . aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) . blood disorders . confusion . convulsions . hepatic damage . hyperglycaemia . interstitial fibrosis associated with NSAIDs can lead to renal failure . intestinal strictures . pancreatitis . papillary necrosis associated with NSAIDs can lead to renal failure . peripheral neuropathy . psychiatric disturbances . pulmonary eosinophilia . Stevens-Johnson syndrome . syncope . thrombocytopenia . toxic epidermal necrolysis . visual disturbances Frequency not known Angioedema . blood disorders . bronchospasm . colitis (induction of or exacerbation of) . Crohn’s disease (induction of or exacerbation of) . depression . diarrhoea . dizziness . drowsiness . fluid retention (rarely precipitating congestive heart failure) . gastro-intestinal bleeding . gastro-intestinal discomfort . gastro-intestinal disturbances . gastro-intestinal ulceration . haematuria . headache . hearing disturbances . hyperkalaemia . hypersensitivity reactions . insomnia . nausea . nervousness . photosensitivity . raised blood pressure . rashes . renal failure (especially in patients with pre-existing renal impairment) . tinnitus . vertigo
PREGNANCY Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of labour may be delayed and its duration may be increased. BREAST FEEDING Use with caution during breast-feeding. Manufacturer advises avoid.
Store in a cool and dry place, below 25℃ and away from light.
.png&w=384&q=75)